• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by FibroGen Inc

    2/10/22 5:07:55 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FGEN alert in real time by email
    SC 13G 1 f021022a.htm SCHEDULE 13G
    240.13d-102 Schedule 13G - Information to be included in statements filed
    pursuant to 240.13d-1(b), (c), and (d) and amendments thereto
    filed pursuant to 240.13d-2.
    Securities and Exchange Commission, Washington, D.C. 20549
    Schedule 13G
    Under the Securities Exchange Act of 1934
    (Amendment No._)*
    (Name of Issuer)
    Fibrogen, Inc.
    (Title of Class of Securities)
    Common Stock, $0.01 Par Value Per Share

    (CUSIP Number)

    31572Q808

    (Date of Event Which Requires Filing of this Statement)
    January 31, 2022
    Check the appropriate box to designate the rule pursuant to which this
    Schedule is filed:
    [  ] Rule 13d-1(b)
    [ x ] Rule 13d-1(c)
    [  ] Rule 13d-1(d)
    *The remainder of this cover page shall be filled out for a reporting person's
    initial filing on this form with respect to the subject class of securities, and
    for any subsequent amendment containing information which would alter the
    disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be
    deemed to be “filed” for the purpose of Section 18 of the Securities Exchange
    Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the
    Act but shall be subject to all other provisions of the Act (however, see
    the Notes).




    CUSIP No. 31572Q808
    (1) Names of reporting persons    Point72 Asset Management, L.P.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              4,613,705 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       4,613,705 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    4,613,705 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 5.0% (see Item 4)
     
    (12) Type of reporting person (see instructions) PN
     


    CUSIP No. 31572Q808
    (1) Names of reporting persons    Point72 Capital Advisors, Inc.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              4,613,705 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       4,613,705 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    4,613,705 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 5.0% (see Item 4)
     
    (12) Type of reporting person (see instructions) CO
     


    CUSIP No. 31572Q808
    (1) Names of reporting persons    Cubist Systematic Strategies, LLC
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              52,402 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       52,402 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    52,402 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 0.1% (see Item 4)
     
    (12) Type of reporting person (see instructions) OO
     


    CUSIP No. 31572Q808
    (1) Names of reporting persons    Steven A. Cohen
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization United States
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              4,666,107 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       4,666,107 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    4,666,107 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 5.0% (see Item 4)
     
    (12) Type of reporting person (see instructions) IN
     



    Item 1(a) Name of issuer:
    Fibrogen, Inc.
    Item 1(b) Address of issuer's principal executive offices:
    409 Illinois Street, San Francisco, CA 94158
    2(a) Name of person filing:
    This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset
    Management”) with respect to shares of common stock, $0.01 par value per
    share (“Shares”), of the Issuer held by certain investment funds it manages;
    (ii) Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with
    respect to Shares held by certain investment funds managed by Point72 Asset
    Management; (iii) Cubist Systematic Strategies, LLC (“Cubist Systematic
    Strategies”) with respect to Shares held by certain investment funds it
    manages; and (iv) Steven A. Cohen (“Mr. Cohen”) with respect to Shares
    beneficially owned by Point72 Asset Management, Point72 Capital Advisors Inc.,
    and Cubist Systematic Strategies.

    Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic
    Strategies, and Mr. Cohen have entered into a Joint Filing Agreement, a copy of
    which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they
    have agreed to file this Schedule 13G jointly in accordance with the
    provisions of Rule 13d-1(k) of the Act.
    2(b) Address or principal business office or, if none, residence:
    The address of the principal business office of (i) Point72 Asset Management,
    Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford,
    CT 06902; and (ii) Cubist Systematic Strategies is 55 Hudson Yards, New York,
    NY 10001.
    2(c) Citizenship:
    Point72 Asset Management is a Delaware limited partnership. Point72 Capital
    Advisors Inc. is a Delaware corporation. Cubist Systematic Strategies is a
    Delaware limited liability company. Mr. Cohen is a United States citizen.
    2(d) Title of class of securities:
    Common Stock, $0.01 Par Value Per Share
    2(e) CUSIP Number:
    31572Q808

    Item 3.

    Not applicable

    Item 4. Ownership

    As of the close of business on February 9, 2022:

    1. Point72 Asset Management, L.P.
    (a) Amount beneficially owned: 4,613,705
    (b) Percent of class: 5.0%
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 4,613,705 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 4,613,705

    2. Point72 Capital Advisors, Inc.
    (a) Amount beneficially owned: 4,613,705
    (b) Percent of class: 5.0% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 4,613,705 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 4,613,705

    3. Cubist Systematic Strategies, LLC
    (a) Amount beneficially owned: 52,402
    (b) Percent of class: 0.1%
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 52,402 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 52,402

    4. Steven A. Cohen
    (a) Amount beneficially owned: 4,666,107
    (b) Percent of class: 5.0% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 4,666,107 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 4,666,107

    Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic
    Strategies, and Mr. Cohen own directly no Shares. Pursuant to an investment
    management agreement, Point72 Asset Management maintains investment and voting
    power with respect to the securities held by certain investment funds it manages.
    Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management.
    Pursuant to an investment management agreement, Cubist Systematic Strategies
    maintains investment and voting power with respect to the securities held by
    certain investment funds it manages. Mr. Cohen controls each of Point72 Asset
    Management, Point72 Capital Advisors Inc., and Cubist Systematic Strategies.
    By reason of the provisions of Rule 13d-3 of the Securities Exchange Act of 1934,
    as amended, each of (i) Point72 Asset Management, Point72 Capital Advisors Inc.,
    and Mr. Cohen may be deemed to beneficially own 4,613,705 Shares (constituting
    approximately 5.0% of the Shares outstanding) and (ii) Cubist Systematic Strategies
    and Mr. Cohen may be deemed to beneficially own 52,402 Shares (constituting
    approximately 0.1% of the Shares outstanding). Each of Point72 Asset Management,
    Point72 Capital Advisors Inc., Cubist Systematic Strategies, and Mr. Cohen
    disclaims beneficial ownership of any of the securities covered by this statement.

    Item 5. Ownership of 5 Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof
    the reporting person has ceased to be the beneficial owner of more than
    5 percent of the class of securities, check the following [].

    Item 6.  Ownership of More than 5 Percent on Behalf of Another Person.

    Not applicable

    Item 7.  Identification and Classification of the Subsidiary Which Acquired
    the Security Being Reporting on by the Parent Holding Company or Control
    Person.
    Not applicable
    Item 8. Identification and Classification of Members of the Group

    Not applicable

    Item 9.  Notice of Dissolution of Group.

    Not applicable

    Item 10. Certifications

    By signing below I certify that, to the best of my knowledge and belief,
    the securities referred to above were not acquired and are not held for the purpose
    of or with the effect of changing or influencing the control of the issuer of
    the securities and were not acquired and are not held in connection with or
    as a participant in any transaction having that purpose or effect, other than activities
    solely in connection with a nomination under§ 240.14a-11.


    Signature.  After reasonable inquiry and to the best of my knowledge and belief,
    I certify that the information set forth in this statement is true, complete
    and correct.

    Dated: February 10, 2022

    POINT72 ASSET MANAGEMENT, L.P.
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    POINT72 CAPITAL ADVISORS, INC.
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    CUBIST SYSTEMATIC STRATEGIES, LLC
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    STEVEN A. COHEN
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person
    Get the next $FGEN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FGEN

    DatePrice TargetRatingAnalyst
    8/8/2023$4.00 → $2.00Neutral → Underperform
    BofA Securities
    6/26/2023Buy → Hold
    Stifel
    6/26/2023Buy → Neutral
    BofA Securities
    6/26/2023Outperform → Mkt Perform
    Raymond James
    6/26/2023Outperform → Mkt Perform
    William Blair
    6/2/2023$23.00 → $32.00Hold → Buy
    Stifel
    1/31/2023Mkt Perform → Outperform
    William Blair
    1/26/2023$35.00Mkt Perform → Outperform
    Raymond James
    More analyst ratings

    $FGEN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum

    Name change to Kyntra Bio reflects the newly sharpened focus of the Company on novel therapies with potential for outsized impact in oncology and rare diseaseKyntra Bio will begin trading on Nasdaq under the trading symbol "KYNB" effective January 8th SAN FRANCISCO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), today announced it is rebranding the company to Kyntra Bio, representing the next step of the transformation of the Company and its focus on oncology and rare disease assets. The Company's common stock will begin trading under the new Nasdaq symbol "KYNB" at stock market open on January 8, 2026. "2025 was a transformational year, highlighted by the sale of Fibro

    1/7/26 7:30:00 AM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food and Drug Administration

    Company is on track to file the Phase 3 protocol in the fourth quarter of 2025 SAN FRANCISCO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted roxadustat Orphan Drug Designation for the treatment of myelodysplastic syndromes (MDS). "The Orphan Drug Designation granted to roxadustat for MDS underscores the significant treatment gap in this indication, and highlights patients' need for additional convenient treatments that can provide durable response," said Thane Wettig, Chief Executive Officer of FibroGen. "Roxadustat showed an improvement in transfusion

    12/15/25 7:00:00 AM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit

    SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that the Company will be attending and presenting at the Oppenheimer Movers in Rare Disease Summit being held on December 11, 2025, in New York, NY. Thane Wettig, Chief Executive Officer of FibroGen, will participate in a panel titled Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving Catalysts on Thursday, December 11 at 12:15 PM ET at the Sofitel New York. FibroGen's management team will be available for one-on-one meetings during the conference. Interested investors should contact their representative at Oppenheimer. About FibroGenFibroGen, Inc. is a bi

    12/2/25 4:05:00 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Delucia David covered exercise/tax liability with 52 shares, decreasing direct ownership by 1% to 4,489 units (SEC Form 4)

    4 - FIBROGEN INC (0000921299) (Issuer)

    12/9/25 4:11:01 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Wettig Thane covered exercise/tax liability with 259 shares, decreasing direct ownership by 1% to 24,680 units (SEC Form 4)

    4 - FIBROGEN INC (0000921299) (Issuer)

    12/9/25 4:10:11 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Wettig Thane bought $33,750 worth of shares (3,700 units at $9.12), increasing direct ownership by 17% to 24,939 units (SEC Form 4)

    4 - FIBROGEN INC (0000921299) (Issuer)

    11/17/25 4:42:52 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FGEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Wettig Thane bought $33,750 worth of shares (3,700 units at $9.12), increasing direct ownership by 17% to 24,939 units (SEC Form 4)

    4 - FIBROGEN INC (0000921299) (Issuer)

    11/17/25 4:42:52 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Schoeneck James A bought $119,485 worth of shares (23,567 units at $5.07) (SEC Form 4)

    4 - FIBROGEN INC (0000921299) (Issuer)

    7/2/25 4:33:27 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Wettig Thane bought $50,663 worth of shares (145,000 units at $0.35), increasing direct ownership by 36% to 543,329 units (SEC Form 4)

    4 - FIBROGEN INC (0000921299) (Issuer)

    3/25/25 9:00:05 AM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    FibroGen downgraded by BofA Securities with a new price target

    BofA Securities downgraded FibroGen from Neutral to Underperform and set a new price target of $2.00 from $4.00 previously

    8/8/23 6:27:35 AM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroGen downgraded by Stifel

    Stifel downgraded FibroGen from Buy to Hold

    6/26/23 1:22:02 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroGen downgraded by BofA Securities

    BofA Securities downgraded FibroGen from Buy to Neutral

    6/26/23 1:16:35 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FGEN
    SEC Filings

    View All

    FibroGen Inc filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - FIBROGEN INC (0000921299) (Filer)

    1/7/26 4:15:12 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by FibroGen Inc

    10-Q - FIBROGEN INC (0000921299) (Filer)

    11/10/25 4:11:00 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroGen Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - FIBROGEN INC (0000921299) (Filer)

    11/10/25 4:05:28 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FGEN
    Leadership Updates

    Live Leadership Updates

    View All

    FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors

    SAN FRANCISCO, June 09, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the appointment of Dr. Michael Kauffman to its Board of Directors effective June 4, 2025. "Michael is a well-recognized biotech industry veteran, who brings a wealth of biotech leadership experience to our board," said James Schoeneck, chairman of the board of directors of FibroGen. "His expertise spanning all stages of drug development will be invaluable as FibroGen progresses its pipeline. Michael's deep understanding of oncology will help the company through anticipated near-term clinical milestones and potential value-drivers." "FibroGen has differentiated potential first-in-class assets and

    6/9/25 4:02:00 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroGen Appoints David DeLucia as Chief Financial Officer

    SAN FRANCISCO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the appointment of David DeLucia to Chief Financial Officer (CFO), effective December 16, 2024. The company previously announced that Juan Graham would step down on December 15, 2024. Reporting to Chief Executive Officer Thane Wettig, DeLucia will lead and oversee FibroGen's global finance organization. He has most recently served as FibroGen's Vice President, Head of Corporate Financial Planning and Analysis, Investor Relations, and Treasury. "Having worked closely with David for the past two and a half years, I am extremely confident he has the breadth and depth of experiences and capabili

    12/16/24 8:05:00 AM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

    SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities. The appointment is effective March 11, 2024. "Deyaa's leadership and expertise in oncology research and clinical development, particularly in bringing oncology therapeutics to market, will be key to accelerating our oncology pipeline and bringing novel cancer therapies to patients in need," said Thane Wettig, Chief Executive Officer of FibroGen. "We are excited to welcome him

    3/11/24 7:00:00 AM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FGEN
    Financials

    Live finance-specific insights

    View All

    FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update

    Completed the sale of FibroGen China to AstraZeneca for approximately $220 millionInitiated the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC)Reached agreement with the U.S. Food and Drug Administration (FDA) on important design elements for the pivotal Phase 3 trial for roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high red blood cell (RBC) transfusion burden Final protocol submission anticipated in 4Q 2025 Topline results from the investigator-sponsored study of FG-3246 in combination with enzalutamide in patie

    11/10/25 4:02:00 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroGen to Report Third Quarter 2025 Financial Results

    SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) will announce third quarter 2025 financial results on Monday, November 10 after market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationThe FibroGen management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To access the call by ph

    11/3/25 4:02:00 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update

    Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $210 million, a $50 million increase from initial guidance Net cash held in China at closing now estimated to be approximately $125 millionTransaction expected to close in 3Q 2025 Upon close of sale of FibroGen China, cash runway extended into 2028 Initiation of the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), expected in 3Q 2025 Reached agreement with the U.S. Food and Drug Administration (FDA) on important design elements for a pivotal Phase 3 trial for roxadustat f

    8/11/25 4:02:00 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by FibroGen Inc

    SC 13G/A - FIBROGEN INC (0000921299) (Subject)

    11/14/24 4:52:23 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by FibroGen Inc

    SC 13G/A - FIBROGEN INC (0000921299) (Subject)

    11/12/24 4:01:23 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by FibroGen Inc

    SC 13G/A - FIBROGEN INC (0000921299) (Subject)

    11/12/24 2:33:26 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care